Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


15.04.2019

1 AJR Am J Roentgenol
4 Am J Respir Cell Mol Biol
1 Ann Oncol
6 Ann Thorac Surg
6 Anticancer Res
1 Arch Pathol Lab Med
2 Br J Cancer
2 Cancer Cell
1 Cancer Chemother Pharmacol
2 Cancer Lett
1 Cancer Sci
1 Clin Lung Cancer
1 Eur Respir J
3 Hum Pathol
2 Int J Cancer
1 Int J Oncol
2 J Immunol
1 J Natl Cancer Inst
1 J Thorac Cardiovasc Surg
8 J Thorac Oncol
1 Lancet
3 Lancet Oncol
1 Lung Cancer
1 Lung Cancer (Auckl)
1 Mol Carcinog
1 Oncogene
1 Oncol Rep
1 Oncologist
6 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. WESSELIUS LJ, DeLeon TT, Gotway MB
    A Sarcoidlike Reaction Mimicking Metastatic Malignancy in a Patient With Melanoma Treated With Pembrolizumab.
    AJR Am J Roentgenol. 2018;210:W183-W184.
    PubMed     Text format    


    Am J Respir Cell Mol Biol

  2. MOON EK
    Gamma-Delta T Cells in Lung Cancer Malignant Pleural Effusion. Friend? Foe?
    Am J Respir Cell Mol Biol. 2019 Apr 8. doi: 10.1165/rcmb.2019-0080.
    PubMed     Text format    

  3. PINKERTON KE, Poindexter ME
    Harmful Interruptions: Impact of Smoking Patterns on Tumorigenesis and Emphysema.
    Am J Respir Cell Mol Biol. 2018 Jun 4. doi: 10.1165/rcmb.2018-0151.
    PubMed     Text format    

  4. SINKEVICIUS KW, Bellaria KJ, Barrios J, Pessina P, et al
    E-Cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma.
    Am J Respir Cell Mol Biol. 2018;59:237-245.
    PubMed     Text format     Abstract available

  5. KAMEYAMA N, Chubachi S, Hegab AE, Yasuda H, et al
    Intermittent Exposure to Cigarette Smoke Increases Lung Tumors and the Severity of Emphysema More Than Continuous Exposure.
    Am J Respir Cell Mol Biol. 2018 Feb 14. doi: 10.1165/rcmb.2017-0375.
    PubMed     Text format     Abstract available


    Ann Oncol

  6. KIM CG, Kim KH, Pyo KH, Xin CF, et al
    Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Ann Oncol. 2019 Apr 12. pii: 5448854. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  7. TSUNEZUKA H, Miyata N, Furuya T, Konishi E, et al
    Spontaneous Regression of Primary Pulmonary Synovial Sarcoma.
    Ann Thorac Surg. 2018;105:e129-e131.
    PubMed     Text format     Abstract available

  8. WOLF A, Liu B, Leoncini E, Nicastri D, et al
    Outcomes for Thoracoscopy Versus Thoracotomy Not Just Technique Dependent: A Study of 9,787 Patients.
    Ann Thorac Surg. 2018;105:886-891.
    PubMed     Text format     Abstract available

  9. STERBLING HM, Rosen AK, Hachey KJ, Vellanki NS, et al
    Caprini Risk Model Decreases Venous Thromboembolism Rates in Thoracic Surgery Cancer Patients.
    Ann Thorac Surg. 2018 Jan 31. pii: S0003-4975(17)31380.
    PubMed     Text format     Abstract available

  10. PREDINA JD, Newton AD, Keating J, Dunbar A, et al
    A Phase I Clinical Trial of Targeted Intraoperative Molecular Imaging for Pulmonary Adenocarcinomas.
    Ann Thorac Surg. 2018 Feb 1. pii: S0003-4975(17)31381.
    PubMed     Text format     Abstract available

  11. BAISI A, Raveglia F, De Simone M, Cioffi U, et al
    TNM Staging System and Surgical Resection for Partially Solid Lung Adenocarcinoma.
    Ann Thorac Surg. 2018;105:989-990.
    PubMed     Text format    

  12. BAISI A, Raveglia F, De Simone M, Cioffi U, et al
    Uniportal Video-Assisted Thoracic Surgery for Pneumothorax: Real Alternative to Multiportal?
    Ann Thorac Surg. 2018;105:1281.
    PubMed     Text format    


    Anticancer Res

  13. CHECK JH, Check D, Poretta T
    Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
    Anticancer Res. 2019;39:1923-1926.
    PubMed     Text format     Abstract available

  14. SHINOHARA S, Otsuki R, Onitsuka T, Machida K, et al
    Postoperative C-reactive Protein Is a Predictive Biomarker for Survival After Non-small Cell Lung Cancer Resection.
    Anticancer Res. 2019;39:2193-2198.
    PubMed     Text format     Abstract available

  15. TAKADA K, Shimokawa M, Akamine T, Ono Y, et al
    Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:1987-1996.
    PubMed     Text format     Abstract available

  16. KURIHARA E, Shien K, Torigoe H, Takeda T, et al
    Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:1767-1775.
    PubMed     Text format     Abstract available

  17. YAN L, Sundaram S, Mehus AA, Picklo MJ, et al
    Time-restricted Feeding Attenuates High-fat Diet-enhanced Spontaneous Metastasis of Lewis Lung Carcinoma in Mice.
    Anticancer Res. 2019;39:1739-1748.
    PubMed     Text format     Abstract available

  18. SUNDARAM S, Yan L
    Adipose-specific Monocyte Chemotactic Protein-1 Deficiency Reduces Pulmonary Metastasis of Lewis Lung Carcinoma in Mice.
    Anticancer Res. 2019;39:1729-1738.
    PubMed     Text format     Abstract available


    Arch Pathol Lab Med

  19. HUANG RSP, Holmes BF, Powell C, Marati RV, et al
    Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics.
    Arch Pathol Lab Med. 2019 Apr 8. doi: 10.5858/arpa.2018-0497.
    PubMed     Text format     Abstract available


    Br J Cancer

  20. HEIM L, Kachler K, Siegmund R, Trufa DI, et al
    Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.
    Br J Cancer. 2019 Apr 8. pii: 10.1038/s41416-019-0444.
    PubMed     Text format     Abstract available

  21. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    PubMed     Text format     Abstract available


    Cancer Cell

  22. FANG L, Teng H, Wang Y, Liao G, et al
    SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.
    Cancer Cell. 2018;34:103-118.
    PubMed     Text format     Abstract available

  23. ZENG H, Jorapur A, Shain AH, Lang UE, et al
    Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
    Cancer Cell. 2018;34:56-68.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  24. KIVRAK SALIM D, Akin Telli T, Tatli AM, Kilickap S, et al
    Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Apr 9. pii: 10.1007/s00280-019-03839.
    PubMed     Text format     Abstract available


    Cancer Lett

  25. DU Q, Yan C, Wu SG, Zhang W, et al
    Development and validation of a novel diagnostic nomogram model based on tumor markers for assessing cancer risk of pulmonary lesions: A multicenter study in Chinese population.
    Cancer Lett. 2018;420:236-241.
    PubMed     Text format     Abstract available

  26. GUERARD M, Robin T, Perron P, Hatat AS, et al
    Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI.
    Cancer Lett. 2018;420:146-155.
    PubMed     Text format     Abstract available


    Cancer Sci

  27. SAKAI K, Ohira T, Matsubayashi J, Yoneshige A, et al
    Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.
    Cancer Sci. 2019 Apr 10. doi: 10.1111/cas.14016.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  28. VOONG KR, Liang OS, Dugan P, Torto D, et al
    Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients With Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2019 Mar 12. pii: S1525-7304(19)30060.
    PubMed     Text format     Abstract available


    Eur Respir J

  29. RAYMAKERS AJN, Sadatsafavi M, Sin DD, FitzGerald JM, et al
    Inhaled corticosteroids and the risk of lung cancer in chronic obstructive pulmonary disease (COPD): a population-based cohort study.
    Eur Respir J. 2019 Apr 7. pii: 13993003.01257-2018.
    PubMed     Text format     Abstract available


    Hum Pathol

  30. ZHANG M, Li G, Sun X, Ni S, et al
    MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma.
    Hum Pathol. 2018;77:108-115.
    PubMed     Text format     Abstract available

  31. LIU J, Lu F, Gong Y, Zhao C, et al
    High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma.
    Hum Pathol. 2018;77:54-62.
    PubMed     Text format     Abstract available

  32. PYO JS, Park MJ, Kang DW
    The clinicopathological significance of micropapillary pattern in colorectal cancers.
    Hum Pathol. 2018;77:159-165.
    PubMed     Text format     Abstract available


    Int J Cancer

  33. D'ANDREA E, Choudhry NK, Raby B, Weinhouse GL, et al
    A bronchial-airway gene-expression classifier to improve the diagnosis of lung cancer: clinical outcomes and cost-effectiveness analysis.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32333.
    PubMed     Text format     Abstract available

  34. WANG S, Zhang J, He Z, Wu K, et al
    The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32327.
    PubMed     Text format     Abstract available


    Int J Oncol

  35. JIN X, Luan H, Chai H, Yan L, et al
    Netrin1 interference potentiates epithelialtomesenchymal transition through the PI3K/AKT pathway under the hypoxic microenvironment conditions of nonsmall cell lung cancer.
    Int J Oncol. 2019 Feb 15. doi: 10.3892/ijo.2019.4716.
    PubMed     Text format     Abstract available


    J Immunol

  36. FLORES-VILLANUEVA PO, Ganachari M, Guio H, Mejia JA, et al
    An Isolated TCR alphabeta Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8(+) T Cells To Kill and Secrete IFN-gamma in Response to Lung Adenocarcinoma Cell Lines.
    J Immunol. 2018;200:2965-2977.
    PubMed     Text format     Abstract available

  37. REGAN DP, Coy JW, Chahal KK, Chow L, et al
    The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment.
    J Immunol. 2019 Apr 10. pii: jimmunol.1800619. doi: 10.4049/jimmunol.1800619.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  38. ROBBINS HA, Berg CD, Cheung LC, Chaturvedi AK, et al
    Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result.
    J Natl Cancer Inst. 2019 Apr 12. pii: 5445482. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  39. STILES BM, Mao J, Harrison S, Lee B, et al
    Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer </=2 cm.
    J Thorac Cardiovasc Surg. 2019 Feb 28. pii: S0022-5223(19)30533.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  40. KRATZ JR, Haro GJ, Cook NR, He J, et al
    Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    J Thorac Oncol. 2019 Apr 5. pii: S1556-0864(19)30270.
    PubMed     Text format     Abstract available

  41. SENAN S, Rusthoven CG, Slotman BJ, Siva S, et al
    Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017.
    J Thorac Oncol. 2018;13:488-496.
    PubMed     Text format     Abstract available

  42. RAEZ LE, Pinto JA, Schrock AB, Ali SM, et al
    EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
    J Thorac Oncol. 2018;13:e33-e34.
    PubMed     Text format    

  43. MICHELS S, Massuti B, Schildhaus HU, Franklin J, et al
    Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial.
    J Thorac Oncol. 2019 Apr 9. pii: S1556-0864(19)30276.
    PubMed     Text format     Abstract available

  44. YIN J, Zhang Y, Zhang Y, Peng F, et al
    Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib.
    J Thorac Oncol. 2018;13:e43-e45.
    PubMed     Text format    

  45. FAN J, Dai X, Nie X
    Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
    J Thorac Oncol. 2018;13:e45-e48.
    PubMed     Text format    

  46. MEANEY C, Mitchell KA, Zingone A, Brown D, et al
    Circulating Inflammation Proteins Associated with Lung Cancer in African Americans.
    J Thorac Oncol. 2019 Apr 3. pii: S1556-0864(19)30269.
    PubMed     Text format     Abstract available

  47. RIHAWI K, Cinausero M, Fiorentino M, Salvagni S, et al
    Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.
    J Thorac Oncol. 2018;13:e41-e43.
    PubMed     Text format    


    Lancet

  48. MOK TSK, Wu YL, Kudaba I, Kowalski DM, et al
    Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)32409.
    PubMed     Text format     Abstract available


    Lancet Oncol

  49. SAITO H, Fukuhara T, Furuya N, Watanabe K, et al
    Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
    Lancet Oncol. 2019 Apr 8. pii: S1470-2045(19)30035.
    PubMed     Text format     Abstract available

  50. GREGORC V, Gaafar RM, Favaretto A, Grossi F, et al
    NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet Oncol. 2018;19:799-811.
    PubMed     Text format     Abstract available

  51. LUCAS C
    Miracle mineral or mesothelioma: cancer and asbestos in the USA.
    Lancet Oncol. 2018;19:868.
    PubMed     Text format    


    Lung Cancer

  52. PARK BJ, Cho JH, Lee JH, Shin S, et al
    Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.
    Lung Cancer. 2018;117:7-13.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  53. BRONTE G, Ulivi P, Verlicchi A, Cravero P, et al
    Targeting RET-rearranged non-small-cell lung cancer: future prospects.
    Lung Cancer (Auckl). 2019;10:27-36.
    PubMed     Text format     Abstract available


    Mol Carcinog

  54. CHEN QY, Li J, Sun H, Wu F, et al
    Role of miR-31 and SATB2 in arsenic-induced malignant BEAS-2B cell transformation.
    Mol Carcinog. 2018;57:968-977.
    PubMed     Text format     Abstract available


    Oncogene

  55. DUAN L, Perez RE, Chastain PD 2nd, Mathew MT, et al
    JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
    Oncogene. 2019 Apr 9. pii: 10.1038/s41388-019-0814.
    PubMed     Text format     Abstract available


    Oncol Rep

  56. YANG Y, Yang CL, Zhao ZJ, Zuo XX, et al
    Microwave hyperthermia enhances the sensitivity of lung cancer cells to gemcitabine through reactive oxygen speciesinduced autophagic death.
    Oncol Rep. 2019 Mar 22. doi: 10.3892/or.2019.7085.
    PubMed     Text format     Abstract available


    Oncologist

  57. SEQUIST LV, Gray JE, Harb WA, Lopez-Chavez A, et al
    Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Oncologist. 2019 Apr 11. pii: theoncologist.2018-0695.
    PubMed     Text format     Abstract available


    PLoS One

  58. GERMONPRE P, Van den Wyngaert T
    Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
    PLoS One. 2019;14:e0215135.
    PubMed     Text format     Abstract available

  59. ZABLOCKA-SLOWINSKA K, Placzkowska S, Skorska K, Prescha A, et al
    Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism.
    PLoS One. 2019;14:e0215246.
    PubMed     Text format     Abstract available

  60. O'FLAHERTY L, Shnyder SD, Cooper PA, Cross SJ, et al
    Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer.
    PLoS One. 2019;14:e0214610.
    PubMed     Text format     Abstract available

  61. NAKANO H, Kawahara D, Ono K, Akagi Y, et al
    Effect of dose-delivery time for flattened and flattening filter-free photon beams based on microdosimetric kinetic model.
    PLoS One. 2018;13:e0206673.
    PubMed     Text format     Abstract available

  62. DOU TH, Coroller TP, van Griethuysen JJM, Mak RH, et al
    Peritumoral radiomics features predict distant metastasis in locally advanced NSCLC.
    PLoS One. 2018;13:e0206108.
    PubMed     Text format     Abstract available

  63. DOMPE N, Klijn C, Watson SA, Leng K, et al
    A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
    PLoS One. 2018;13:e0199264.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: